tradingkey.logo

Fortrea Holdings Inc

FTRE
查看详细走势图
14.650USD
+0.850+6.16%
收盘 02/06, 16:00美东报价延迟15分钟
1.35B总市值
亏损市盈率 TTM

Fortrea Holdings Inc

14.650
+0.850+6.16%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+6.16%

5天

-12.85%

1月

-16.24%

6月

+102.35%

今年开始到现在

-15.07%

1年

-1.74%

查看详细走势图

TradingKey Fortrea Holdings Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Fortrea Holdings Inc当前公司基本面数据相对稳定,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名63/392位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价16.80。中期看,股价处于上升通道。近一个月,市场表现非常差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Fortrea Holdings Inc评分

相关信息

行业排名
63 / 392
全市场排名
183 / 4521
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Fortrea Holdings Inc亮点

亮点风险
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.

分析师目标

根据 11 位分析师
持有
评级
16.800
目标均价
+4.61%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Fortrea Holdings Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Fortrea Holdings Inc简介

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
公司代码FTRE
公司Fortrea Holdings Inc
CEOThakrala (Anshul)
网址https://www.fortrea.com/
KeyAI